Risankizumab outperforms deucravacitinib in moderate psoriasis, interim trial data show
From the article
Risankizumab produces greater clinical and patient-reported benefits than deucravacitinib in biologic-naive adults with moderate plaque psoriasis, according to preliminary findings from the IMMpactful trial. Choosing the optimal first-line systemic therapy for patients with moderate plaque psoriasis has become increasingly complex with the availability of newer oral and biologic agents. However, direct comparative evidence has been […] The post Risankizumab outperforms deucravacitinib in moderate psoriasis, interim trial data show appeared first on Hospital Healthcare Europe .
Continue reading on hospitalhealthcare.comYou might also wanna read
Patient Engagement With Dermatology Visit Notes Remains Low
Medscape·14h ago
Delgocitinib cream linked to low systemic exposure in chronic hand eczema, post hoc analysis shows
hospitalhealthcare.com·5d ago
Bidirectional phenotype switching between psoriasis and atopic dermatitis characterised
hospitalhealthcare.com·6d ago
Postpartum Hyperpigmentation in a 35-Year-Old Woman: A Clinical Case Presentation
A 35-year-old Black woman of Hispanic ethnicity presented 4 months postpartum with hyperpigmented lines on her lower extremities that develo
ja.ma·17d ago
Demodex Mites: Understanding the Microscopic Organisms Living on Human Skin
Demodex mites are microscopic parasites that naturally live on human skin, primarily in hair follicles and oil glands on the face, neck, and
wb.md·18d ago
Skin inflammation as a sentinel marker for neurodegeneration: Chronic skin disorders may signal dementia risk in older adults
This article discusses the emerging link between chronic inflammatory skin conditions and dementia risk in older adults. It highlights that
pubmed.ncbi.nlm.nih.gov·19d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.